Generation of Tissue Engineered Nerve Grafts from GalSafe Porcine Neurons
利用 GalSafe 猪神经元生成组织工程神经移植物
基本信息
- 批准号:10473788
- 负责人:
- 金额:$ 90.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-30 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAddressAnimal ModelAntigensAutologous TransplantationAxonBenchmarkingBiological ProductsBiomanufacturingBiomassBrachial plexus structureCaringCellsClinicalClinical TrialsCryopreservationCyclic GMPDataDefectDistalDistantEnsureFaceFamily suidaeGalactoseGenerationsGenetic EngineeringGoldGraft SurvivalGrowthHandHarvestHealthHumanImageImmune responseImplantIn VitroInjuryLactate DehydrogenaseLeadLengthLesionLicensingLifeMeasuresMedicalMetabolicMethodsModelingMotorNerveNerve RegenerationNervous System TraumaNeurodegenerative DisordersNeuronsOperative Surgical ProceduresOutcomePatientsPeripheral nerve injuryPhasePopulationProbabilityProcessProtocols documentationQuality of lifeRecoveryRecovery of FunctionRodentRodent ModelSmall Business Innovation Research GrantSourceStainsSterilityStretchingTarget PopulationsTechniquesTestingTissue EngineeringTranslationsTransplantationTransportationTraumaUpper armValidationafferent nerveaxon regenerationbasebiofabricationclinical practiceclinical translationcomplement systemcostdensityefficacy studyefficacy testingfunctional restorationimmunocytochemistryimprovedin vivoinjury and repairmeetingsnerve autograftnext generationporcine modelpre-clinicalpreservationproduct developmentprogramsquality assurancereconstructionregenerativereinnervationrepairedresearch clinical testingsafety studyscaffoldsuccess
项目摘要
PROJECT SUMMARY
Tissue engineered medical products have tremendous promise to address the currently irreparable effects of
neurotrauma and/or neurodegenerative diseases. Axonova Medical’s lead product, the tissue engineered nerve
graft (TENG), is a bioactive “living scaffold” proven to promote rapid nerve regeneration and functional restoration
when implanted to repair major peripheral nerve injury (PNI). Implementing living neuronal cells as the starting
biomass, Axonova routinely biomanufactures TENGs comprised of living, long, aligned axon tracts through the
proprietary process of axon “stretch-growth”. To date, TENGs have been shown to consistently promote host
axon regeneration and improve functional recovery compared to current clinical practices in both small and large
animal models of PNI, including the repair of 5 cm segmental defects. In order to move to a manufacturing-
compliant biomass, Axonova has partnered with Revivicor to generate GalSafe® TENGs using their genetically
engineered porcine neurons to mitigate a host immune response upon eventual transplantation in humans.
Through the Phase I efforts, GalSafe® TENGs were successfully stretch-grown to create products at lengths of
1 cm, 3 cm, and 5 cm with a health and axon density that met or exceeded established quality benchmarks.
Moreover, 1 cm TENGs were transplanted into a rodent PNI model to demonstrate regenerative efficacy,
revealing that GalSafe® TENGs survived as well as actively drove host axonal regeneration via the proprietary
mechanism-of-action of TENGs, referred to as axon facilitated axon regeneration (AFAR). Along with choosing
a safe and readily available starting biomass, other product development challenges include biopreservation and
quality assurance criteria to allow increased shelf life, transportation, and maintained efficacy of the product.
Accordingly, the current Phase II SBIR program addresses a key facet of clinical grade biomanufacturing,
specifically the validation of an effective storage protocol and release criteria ensuring product health, sterility,
and potency. TENGs will be biofabricated from a cGMP-compliant cell source (GalSafe® porcine neurons), cold-
stored using a cGMP-compliant preservation protocol, and then tested in small and large animal models of PNI
to demonstrate regenerative efficacy. Specifically, Axonova will systematically complete the objectives of this
program across 3 Specific Aims: (1) determine the efficacy of fresh GalSafe® TENGs in an established porcine
PNI model; (2) effectively biopreserve GalSafe® TENGs to increase shelf-life and validate non-invasive release
criteria; and (3) determine the potency and efficacy of biopreserved GalSafe® TENGs in vivo in rodent and
porcine PNI models. This program addresses a major challenge in the translation of next-generation tissue
engineered medical products by validating manufacturing, storage and release criteria for a living biological
product to enable eventual testing in humans. The ability to store and distribute GalSafe® TENGs as an “off-the-
shelf” product will vastly increase commercial potential by reducing costs and expanding patient access, thereby
improving recovery and quality of life for patients suffering from the debilitating effects of major PNI.
项目摘要
组织工程医疗产品具有巨大的前景,以解决目前无法弥补的影响,
神经创伤和/或神经变性疾病。Axonova医疗公司的主导产品,组织工程神经
TENG是一种具有生物活性的“活支架”,被证明可以促进神经的快速再生和功能恢复
当植入以修复主要周围神经损伤(PNI)时。将活的神经元细胞作为
生物质,Axonova通常生物制造TENG,由活的,长的,排列的轴突束组成,通过
轴突“伸展生长”的专有过程。迄今为止,TENG已被证明一贯促进宿主
轴突再生和改善功能恢复相比,目前的临床实践中,无论是小的和大的
PNI的动物模型,包括5cm节段性缺损的修复。为了转移到制造业-
符合生物质标准,Axonova与Revivicor合作,利用其基因技术生产GalSafe® TENG。
工程化的猪神经元以减轻最终移植到人体后的宿主免疫反应。
通过第一阶段的努力,GalSafe® TENG成功地拉伸生长,生产出长度为
1 cm、3 cm和5 cm,其健康和轴突密度达到或超过既定质量基准。
此外,将1cm TENG移植到啮齿动物PNI模型中以证明再生功效,
揭示了GalSafe® TENG的存活并通过专有技术积极驱动宿主轴突再生
TENG的作用机制,称为轴突促进轴突再生(AFAR)。沿着选择
安全和容易获得的起始生物质,其他产品开发挑战包括生物保护和
质量保证标准,以延长产品的保质期、运输和保持产品的功效。
因此,目前的第二阶段SBIR计划解决了临床级生物制造的一个关键方面,
特别是验证有效的储存方案和放行标准,确保产品健康,无菌,
和力量TENG将由符合cGMP的细胞来源(GalSafe®猪神经元)生物制造,
使用符合cGMP的保存方案储存,然后在PNI的小型和大型动物模型中进行测试
来证明再生功效具体来说,Axonova将系统地完成这一目标,
该计划跨越3个具体目标:(1)确定新鲜GalSafe® TENG在已建立的猪
PNI模型;(2)有效地生物保护GalSafe® TENG,以延长保质期并验证非侵入性释放
标准;和(3)确定生物保存的GalSafe® TENG在啮齿动物体内的效力和功效,以及
猪PNI模型。该计划解决了下一代组织翻译中的一个重大挑战
通过验证活生物制品的制造、储存和放行标准,
产品,使最终在人类身上进行测试。能够将GalSafe® TENG作为一种“离线”存储和分发,
货架”产品将通过降低成本和扩大患者可及性而极大地增加商业潜力,
改善患有主要PNI的衰弱效应的患者的恢复和生活质量。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kritika Katiyar其他文献
Kritika Katiyar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kritika Katiyar', 18)}}的其他基金
Development of Tissue Engineered Neuromuscular Interfaces from GalSafe Neurons.
从 GalSafe 神经元开发组织工程神经肌肉接口。
- 批准号:
10385405 - 财政年份:2022
- 资助金额:
$ 90.1万 - 项目类别:
Generation of Tissue Engineered Nerve Grafts from GalSafe Porcine Neurons
利用 GalSafe 猪神经元生成组织工程神经移植物
- 批准号:
10268167 - 财政年份:2018
- 资助金额:
$ 90.1万 - 项目类别:
Generation of Tissue Engineered Nerve Grafts from GalSafe Porcine Neurons
利用 GalSafe 猪神经元生成组织工程神经移植物
- 批准号:
10011078 - 财政年份:2018
- 资助金额:
$ 90.1万 - 项目类别:
Mechanisms for Axonal Guidance Using Living Tissue Engineered Scaffolds
使用活组织工程支架进行轴突引导的机制
- 批准号:
8983595 - 财政年份:2015
- 资助金额:
$ 90.1万 - 项目类别:
Mechanisms for Axonal Guidance Using Living Tissue Engineered Scaffolds
使用活组织工程支架进行轴突引导的机制
- 批准号:
9335678 - 财政年份:2015
- 资助金额:
$ 90.1万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 90.1万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 90.1万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 90.1万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 90.1万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 90.1万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 90.1万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 90.1万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 90.1万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 90.1万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 90.1万 - 项目类别:
Research Grant